Mantle Cell Lymphoma | Specialty

The mantle cell lymphoma condition center is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma. Read more at OncLive.

FDA Approves Tablet Formulation of Zanubrutinib for B-Cell Malignancies

June 11th 2025

The FDA has approved a tablet formulation of zanubrutinib for use in all 5 approved indications of the capsule formulation.

Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress

June 6th 2025

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

MAIC Analysis Reveals Long-Term PFS Benefit With Zanubrutinib Over Orelabrutinib in R/R MCL

May 28th 2025

Findings from a matching-adjusted indirect comparison showed a PFS benefit with zanubrutinib vs orelabrutinib in relapsed/refractory mantle cell lymphoma.

Dr Kahl on Persisting Unmet Needs in the Treatment of Mantle Cell Lymphoma

May 26th 2025

Brad Kahl, MD, discusses the ongoing unmet needs in the treatment of mantle cell lymphoma.

Dr Kahl on the Rationale for Adding Bortezomib to BR Induction in MCL

May 19th 2025

Brad S. Kahl, MD, explains the importance of identifying less intensive induction regimens for older patients with mantle cell lymphoma.

Dr Dreyling on Investigating ASCT Plus Ibrutinib and R-CHOP in Younger, Fit Patients With MCL

May 19th 2025

Martin Dreyling, MD, discusses the patient population studied in the TRIANGLE trial of ASCT plus ibrutinib-containing therapy in younger patients with MCL.

Large Clonal Hematopoiesis Clones Are Associated With Worse Survival Outcomes in MCL

May 13th 2025

Patients with MCL and large clonal hematopoiesis clones experienced shortened PFS and OS vs those without clones.

Bendamustine/Rituximab Represents a Backbone for Therapeutic Development in MCL

May 10th 2025

Brad S. Kahl, MD, details the evaluation of induction BR plus bortezomib with rituximab/lenalidomide maintenance in mantle cell lymphoma.

Dr Fenske on Assessing the Role of Auto-HCT in the Current MCL Treatment Paradigm

May 9th 2025

Timothy S. Fenske, MD, MS, discusses the rationale for evaluating the role of standard auto-HCT in MCL given recent updates to the MCL treatment paradigm.

Dr Kahl on the Outcomes of Bortezomib Plus BR in MCL

May 8th 2025

Brad S. Kahl, MD, details the outcomes of bortezomib plus bendamustine/rituximab in patients with mantle cell lymphoma.

Pooled Analysis Shows POD24 Strongly Predicts Poor Survival in Newly Diagnosed MCL

May 6th 2025

Early progression or death within 24 months of first-line treatment was linked to inferior survival in mantle cell lymphoma.

Acalabrutinib Plus BR Wins EU Approval for Previously Untreated, Transplant-Ineligible Mantle Cell Lymphoma

May 6th 2025

The European Commission has approved acalabrutinib plus bendamustine and rituximab for previously untreated, transplant-ineligible mantle cell lymphoma.

LV20.19 CAR T-Cell Therapy Yields 100% ORR and Manageable Toxicity in R/R MCL

April 18th 2025

On-site adaptive manufacturing of LV20.19 resulted in a high complete response rate and favorable tolerability in relapsed/refractory mantle cell lymphoma.

Ibrutinib/Lenalidomide/Rituximab Yields Long-Term Efficacy in R/R MCL

April 15th 2025

Treatment with the IR2 regimen led to durable responses that were favorable compared with those in chemotherapy-treated relapsed/refractory MCL.

BTK Inhibitor Refractoriness and Platelet Count Are Prognostic for Survival With Brexu-Cel in MCL

April 14th 2025

Patients with MCL who received real-world brexu-cel experienced lower survival when they were BTK inhibitor refractory and/or had lower platelet counts.

Dr van Meerten on the Optimal Use of Brexu-Cel in BTK Inhibitor–Naive MCL

April 11th 2025

Tom van Meerten, MD, PhD, outlines select patient subgroups with BTK inhibitor–naive relapsed/refractory MCL who may benefit from treatment with brexu-cel.

R-DA-EDOCH/R-DHAP Induction Yields Responses and MRD Negativity in Young, High-Risk MCL Population

April 8th 2025

Induction R-DA-EDOCH/R-DHAP therapy yields high rates of CR, overall response, and MRD negativity in young patients with newly diagnosed, high-risk MCL.

Dr Dreyling on the Expanding Role of BTK Inhibitors in the Treatment of MCL

April 4th 2025

Martin Dreyling, MD, discusses the expanding role of BTK inhibitors in the treatment of mantle cell lymphoma.

Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies

April 3rd 2025

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

Brexu-Cel Demonstrates Efficacy, Safety in Older Patients with R/R Mantle Cell Lymphoma

April 2nd 2025

Brexu-cel demonstrated clinical activity and safety in patients over 70 years of age with relapsed/refractory mantle cell lymphoma.